ネクセラファーマの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/01/17 | 966 | 1,013 | 964 | 998 | +62 | +6.6% | 2,354,800 |
| 2025/01/16 | 938 | 949 | 934 | 936 | +5 | +0.5% | 665,100 |
| 2025/01/15 | 968 | 969 | 927 | 931 | -39 | -4% | 1,016,900 |
| 2025/01/14 | 975 | 980 | 961 | 970 | -16 | -1.6% | 869,700 |
| 2025/01/10 | 996 | 997 | 984 | 986 | -17 | -1.7% | 563,800 |
| 2025/01/09 | 1,002 | 1,006 | 996 | 1,003 | -2 | -0.2% | 561,100 |
| 2025/01/08 | 1,023 | 1,028 | 1,005 | 1,005 | -10 | -1% | 458,600 |
| 2025/01/07 | 1,018 | 1,024 | 1,007 | 1,015 | -1 | -0.1% | 528,500 |
| 2025/01/06 | 1,052 | 1,056 | 1,015 | 1,016 | -32 | -3.1% | 659,200 |
| 2024/12/30 | 1,050 | 1,076 | 1,045 | 1,048 | -5 | -0.5% | 515,600 |
| 2024/12/27 | 1,043 | 1,061 | 1,040 | 1,053 | +31 | +3% | 711,100 |
| 2024/12/26 | 1,015 | 1,027 | 1,009 | 1,022 | +6 | +0.6% | 820,300 |
| 2024/12/25 | 1,027 | 1,027 | 1,008 | 1,016 | -17 | -1.6% | 744,600 |
| 2024/12/24 | 1,043 | 1,046 | 1,022 | 1,033 | +11 | +1.1% | 716,300 |
| 2024/12/23 | 1,032 | 1,038 | 1,008 | 1,022 | -12 | -1.2% | 857,300 |
| 2024/12/20 | 1,055 | 1,056 | 1,033 | 1,034 | -18 | -1.7% | 701,100 |
| 2024/12/19 | 1,033 | 1,063 | 1,030 | 1,052 | +8 | +0.8% | 575,700 |
| 2024/12/18 | 1,054 | 1,059 | 1,044 | 1,044 | -17 | -1.6% | 452,300 |
| 2024/12/17 | 1,050 | 1,065 | 1,047 | 1,061 | +7 | +0.7% | 535,200 |
| 2024/12/16 | 1,057 | 1,057 | 1,044 | 1,054 | -3 | -0.3% | 592,700 |
| 2024/12/13 | 1,054 | 1,063 | 1,043 | 1,057 | -22 | -2% | 758,600 |
| 2024/12/12 | 1,089 | 1,103 | 1,076 | 1,079 | -5 | -0.5% | 486,800 |
| 2024/12/11 | 1,110 | 1,114 | 1,078 | 1,084 | -36 | -3.2% | 665,200 |
| 2024/12/10 | 1,131 | 1,136 | 1,120 | 1,120 | +2 | +0.2% | 374,900 |
| 2024/12/09 | 1,090 | 1,152 | 1,090 | 1,118 | +37 | +3.4% | 1,098,000 |
| 2024/12/06 | 1,085 | 1,097 | 1,071 | 1,081 | -4 | -0.4% | 571,900 |
| 2024/12/05 | 1,100 | 1,106 | 1,084 | 1,085 | -4 | -0.4% | 671,200 |
| 2024/12/04 | 1,105 | 1,108 | 1,087 | 1,089 | -23 | -2.1% | 633,700 |
| 2024/12/03 | 1,140 | 1,148 | 1,112 | 1,112 | -16 | -1.4% | 459,900 |
| 2024/12/02 | 1,123 | 1,132 | 1,118 | 1,128 | +9 | +0.8% | 324,300 |
| 2024/11/29 | 1,127 | 1,136 | 1,113 | 1,119 | -21 | -1.8% | 465,900 |
| 2024/11/28 | 1,137 | 1,153 | 1,136 | 1,140 | +4 | +0.4% | 298,300 |
| 2024/11/27 | 1,120 | 1,139 | 1,111 | 1,136 | +26 | +2.3% | 594,700 |
| 2024/11/26 | 1,126 | 1,134 | 1,100 | 1,110 | -26 | -2.3% | 602,100 |
| 2024/11/25 | 1,139 | 1,162 | 1,124 | 1,136 | +4 | +0.4% | 693,500 |
| 2024/11/22 | 1,141 | 1,145 | 1,127 | 1,132 | -5 | -0.4% | 370,400 |
| 2024/11/21 | 1,131 | 1,146 | 1,124 | 1,137 | +17 | +1.5% | 617,200 |
| 2024/11/20 | 1,110 | 1,122 | 1,103 | 1,120 | +16 | +1.4% | 499,200 |
| 2024/11/19 | 1,115 | 1,128 | 1,100 | 1,104 | -15 | -1.3% | 1,328,000 |
| 2024/11/18 | 1,163 | 1,167 | 1,119 | 1,119 | -47 | -4% | 918,400 |
| 2024/11/15 | 1,167 | 1,177 | 1,155 | 1,166 | +3 | +0.3% | 466,400 |
| 2024/11/14 | 1,177 | 1,184 | 1,161 | 1,163 | -12 | -1% | 450,000 |
| 2024/11/13 | 1,200 | 1,200 | 1,174 | 1,175 | -27 | -2.2% | 621,300 |
| 2024/11/12 | 1,237 | 1,254 | 1,199 | 1,202 | +8 | +0.7% | 1,345,300 |
| 2024/11/11 | 1,192 | 1,198 | 1,176 | 1,194 | -3 | -0.3% | 332,100 |
| 2024/11/08 | 1,195 | 1,209 | 1,191 | 1,197 | +5 | +0.4% | 470,700 |
| 2024/11/07 | 1,195 | 1,203 | 1,174 | 1,192 | -8 | -0.7% | 646,300 |
| 2024/11/06 | 1,189 | 1,222 | 1,179 | 1,200 | +26 | +2.2% | 724,600 |
| 2024/11/05 | 1,230 | 1,256 | 1,169 | 1,174 | -39 | -3.2% | 862,400 |
| 2024/11/01 | 1,200 | 1,221 | 1,200 | 1,213 | -16 | -1.3% | 567,700 |
101～
150
件表示中 / 5111件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ネクセラファーマ | 92,000円 | +20.3% | - | 0.00% | 163.12倍 | 1.22倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| 杏林製薬 | 148,400円 | -2.4% | -52.3% | 3.84% | 17.76倍 | 0.63倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 栄研化 | 220,000円 | +4.1% | -3.1% | 2.64% | 19.16倍 | 1.67倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ＪＣＲファーマ | 55,400円 | +14.3% | - | 3.61% | 22.50倍 | 1.44倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| あすかＨＤ | 233,000円 | +16.9% | +33.2% | 2.36% | 12.71倍 | 1.01倍 |
|
武田と親密。婦人科領域に強い。先発品比率引き上げに注力。２１年春にあすか製薬が持株会社化 |
市場注目の銘柄
チャート関連のコラム
